<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900131</url>
  </required_header>
  <id_info>
    <org_study_id>ISEE_2015_JWG</org_study_id>
    <nct_id>NCT02900131</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients</brief_title>
  <official_title>Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients: a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyung Hee University Hospital at Gangdong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence.&#xD;
      Complementary and alternative medical approaches have been employed to relieve symptoms of&#xD;
      Atopic Dermatitis. We aim to establish basic clinical efficacy and safety data for Jaungo in&#xD;
      patients with Atopic Dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomised, double blind, placebo-controlled, single-centre trial with three&#xD;
      parallel arms (trial group 1, trial group 2, and control group). The diagnosis of Atopic&#xD;
      Dermatitis will be made according to the criteria of Hanifin and Rajka. Participants will&#xD;
      receive Jaungo or a placebo-drug for three weeks. Participants in trial group 1 will apply&#xD;
      Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2&#xD;
      will apply Jaungo to the lesion twice a day for three weeks. Participants in control group&#xD;
      will apply placebo to the lesion twice a day for three weeks. Each participant will be&#xD;
      examined for EASI (Eczema area and severity index), SCORAD (SCORing of Atopic Dermatitis),&#xD;
      TEWL (Transepidermal water loss) and DLQI (Dermatology Life Quality Index) before and after&#xD;
      applying medication. The outcomes to evaluate the maintenance of safety are Draize score,&#xD;
      blood test and expert's opinion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2016</start_date>
  <completion_date type="Actual">March 16, 2017</completion_date>
  <primary_completion_date type="Actual">March 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 'Eczema area and severity index (EASI)'</measure>
    <time_frame>Visit2(scheduled within a week of baseline), Visit3(in 3 weeks after visit2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 'SCORing of Atopic Dermatitis (SCORAD)'</measure>
    <time_frame>Visit2(scheduled within a week of baseline), Visit3(in 3 weeks after visit2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 'Transepidermal water loss (TEWL)'</measure>
    <time_frame>Visit2(scheduled within a week of baseline), Visit3(in 3 weeks after visit2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 'Dermatology Life Quality Index (DLQI)'</measure>
    <time_frame>Visit2(scheduled within a week of baseline), Visit3(in 3 weeks after visit2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 'Total IgE'</measure>
    <time_frame>Visit1, Visit3(in 3 weeks after visit2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical phenotype evaluation system of atopic dermatitis</measure>
    <time_frame>Visit2(scheduled within a week of baseline)</time_frame>
    <description>Evaluation based on the results of 'clinical phenotype evaluation system of atopic dermatitis' questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 'eosinophil count'</measure>
    <time_frame>Visit1, Visit3(in 3 weeks after visit2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 'IL-17'</measure>
    <time_frame>Visit1, Visit3(in 3 weeks after visit2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 'IL-22'</measure>
    <time_frame>Visit1, Visit3(in 3 weeks after visit2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 'IFN-γ'</measure>
    <time_frame>Visit1, Visit3(in 3 weeks after visit2)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>trial group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Jaungo and placebo once a day for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trial group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Jaungo twice a day for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo twice a day for three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaungo</intervention_name>
    <description>Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.</description>
    <arm_group_label>trial group 1</arm_group_label>
    <arm_group_label>trial group 2</arm_group_label>
    <other_name>Hanpoong Jaungo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>trial group 1</arm_group_label>
    <other_name>Jaungo placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The diagnosis of AD will be made according to the criteria of Hanifin and Rajka&#xD;
&#xD;
          2. Age: 5 years to 65 years&#xD;
&#xD;
          3. objective SCORAD ≦40, Diagnosis of Mild to Moderate Atopic Dermatitis (AD)&#xD;
&#xD;
          4. Exoriation≥1, Lichenification≥1, Dryness≥1 or Exoriation+Lichenification+Dryness≥3&#xD;
&#xD;
          5. Participants who able to express intention&#xD;
&#xD;
          6. Participants willing to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants have oozing in the lesion&#xD;
&#xD;
          2. Users of following medications prior to trial periods&#xD;
&#xD;
             ① Oral steroids, immunosuppressants and antibiotics within 4 weeks prior to this trial&#xD;
&#xD;
             ② Topical steroids, immunosuppressants and antibiotics within 2 weeks prior to this&#xD;
             trial&#xD;
&#xD;
             ③ Light therapy within 2 weeks prior to this trial&#xD;
&#xD;
             ④ Other medications thought to be inappropriate by researchers&#xD;
&#xD;
          3. Participants have severe burn or wide wound&#xD;
&#xD;
          4. Participants have oozing or ulcer in the lesion&#xD;
&#xD;
          5. Allergic reactions to Angelica gigas, Siebold et Zuccarini, sesame oil and lard&#xD;
&#xD;
          6. Participants have skin disease except atopic dermatitis&#xD;
&#xD;
          7. Participants have severe renal function disease (sCr &gt; 2.0 mg/dL)&#xD;
&#xD;
          8. Participants have severe liver function disease (ALT, AST, ALP ≥ 2.5 × normal limits)&#xD;
&#xD;
          9. Participants have uncontrolled chronic diseases&#xD;
&#xD;
         10. Pregnancy, lactation&#xD;
&#xD;
         11. Participation in another clinical trial within one month of enrolment&#xD;
&#xD;
         12. Underlying disease or history of severe disease, abnormal state (paralysis; mental&#xD;
             retardation other emotional or mental problems; diseases that can affect the&#xD;
             absorption of drugs; no enough time to participate in this trial; visual disturbance&#xD;
             and hearing impairment; inability to understand written consent or engage in this&#xD;
             study)&#xD;
&#xD;
         13. Judgment by experts that the potential subject's participation is inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong-Kyu Ko, KMD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kyunghee University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Hoegi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyung Hee University Hospital at Gangdong</investigator_affiliation>
    <investigator_full_name>In-Hwa Choi</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

